A group from SystImmune Inc., 15318 NE 95th St., Redmond, WA, 98052, USA, etc. has reported that ACE2-Fc fusion protein could be a good therapeutic drug overcoming viral escape of SARS-CoV-2 variants.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882475/
Interestingly, the pseudovirus neutralization data using the ACE2-Fc fusion protein named SI-F09 (shown below) shows that the higher the binding strength between SARS-CoV-2 RBD and ACE2, the lower the IC50 values. In other words, the IC50 value for WT is the highest among SARS-CoV-2 variants imcruding Omicron.
In the meantime, a phase I clinical trial evaluating safety of SI–F019 in healthy patients has been conducted (ClinicalTrials.gov Identifier: NCT04851444) and is being analyzed in preparation for future clinical studies.